






Electronic Product Information (ePI) for EU medicines










ePI chronology









Definitions



ePI is authorised, statutory product information for medicines (i.e. summary of product characteristics, package leaflet and labelling) in a semi-structured format created using the common EU electronic standard. ePI is **adapted for electronic handling** and allows dissemination via the world wide web, eplatforms and print.



A **common EU electronic standard** for ePI refers to the **technical features** (including mark-up language, controlled vocabularies and interoperability specifications) agreed by regulators and stakeholders. The common standard will be used to generate ePI.







Use cases

Patient



List of her medicines ePI in phone app

Does not remember how to take asthma medicine



Goes to 'How to take your medicine' to downloadable video



Receives alert when ePI updated e.g. new safety information

Links to other material



- **Educational** material
- Lay summaries
- More technical material







Use cases

Healthcare professional

Checks renewal of prescription for chronic condition, new side effect in prescribing system



Approves renewal with:

- message in the personal health record of patient
- contact with patient





- Pregnancy planning
- Lactose intolerance
- Hay fever OTC without drowsiness

Targeted ePI search

Treatment decision







ePI key principles

- ePI and EU common standard definitions
- Expansion of access to information on medicines
- Accessibility to users with diverse abilities
- 4 Creation of efficiencies for regulatory systems
- 5 Complementarity to paper package leaflet








ePI key principles

- Open access to regulator-approved information
- 7 Data protection
- 8 Flexibility in implementation
- Support for multilingual PI
- 10) Interoperability with EU and global initiatives
















Public consultation — stakeholder profile

31 January to 31 July

submissions

>500 comments

comprising










Public consultation — main points & sentiment

- Appetite for widening scope of ePI (e.g. photos of medicines, risk minimisation material, DHPCs)
- Strong wish to also work on PI content
- New key principle on efficiencies in regulatory processes
- Strong views on both sides on principle that ePI complements paper



High interest and encouraging support for initiative with just ~8% negative comments







EU Roadmap — implementation on basis of key principles



ePI set up project defines common standard and provides tools needed for a pilot phase



Pilot by EMA and some pioneer NCAs tests ePI from end-to-end and assesses impact on current processes




Ongoing consultation with patient and HCP representatives







Any questions?



Further information

Juan.Garcia@ema.europa.eu

See websites for contact details **European Medicines Agency** <u>www.ema.europa.eu</u> Heads of Medicines Agencies www.hma.eu **European Commission** <u>www.ec.europa.eu</u>





#ePI4Medicines